• Awards and Honors

    banners on outside of Marcotte Center for Cancer Research at Dana-Farber 

    A selection of awards recently earned by Dana-Farber and our staff

    May – June 2015

    Individuals

    Aldo Roccaro, MD, PhD, has received the Francesco De Luca International Prize 2015 for cancer research from the Accademia dei Lincei, in a ceremony in Rome attended by the President of Italy, Sergio Mattarella. Roccaro is a senior research scientist in the Medical Oncology laboratory of Irene Ghobrial, MD. The Accademia dei Lincei is one of the world's oldest scientific academies; Galileo Galilei was among the first scientists inducted as a member of the academy.

    F. Stephen Hodi, MD, director of Dana-Farber's Center for Immuno-Oncology, and fellow researchers were recognized with the 2015 Herbert Pardes Clinical Research Excellence Award for their 2010 Nature paper on immunotherapy. Given by the Clinical Research Forum, the award recognizes innovative, creative research that affects the understanding of disease and has the potential to impact patient outcomes.

    Pere Puigserver, PhD, a Dana-Farber cancer biology researcher and professor of Cell Biology at Harvard Medical School, received an award for Outstanding Scientific Achievement from the American Diabetes Association (ADA) at its 75th Scientific Sessions meeting. The award is for "outstanding contributions to the molecular understanding of nutrient-regulated metabolic processes that can malfunction to cause diabetes and other metabolic diseases."

    Chief of Staff Emeritus Stephen E. Sallan, MD, received the American Society of Clinical Oncology (ASCO) Pediatric Oncology Award at the organization's annual meeting. This honor recognizes the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology community to enhancing cancer prevention, treatment, and patient care.

    Robert J. Mayer, MD, Dana-Farber faculty vice president for academic affairs, was honored with a Giants of Cancer Care in Gastrointestinal Cancer award in conjunction with ASCO 2015. This is the premier oncology award in the U.S. aiming to recognize and celebrate physicians who have made significant contributions to the cure and treatment of those living with cancer.

    Dana-Farber's Levi Garraway, MD, PhD, has been selected as a Howard Hughes Medical Institute (HHMI) investigator. Garraway, a medical oncologist at Dana-Farber and associate professor of medicine at Harvard Medical School, will receive the flexible support necessary to move his biomedical research in creative new directions over the next five years.

    January – April 2015

    The Institute

    The Commission on Cancer (CoC) has awarded a three-year accreditation to Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), which received three commendations following a site visit in 2014. The CoC, affiliated with the American College of Surgeons, is a consortium of professional organizations committed to improving survival rates and quality of life for cancer patients.

    The United States Environmental Protection Agency (EPA) presented Dana-Farber with the award of Non-Profit Organization Partner of the Year on April 22 — Earth Day. The award recognizes Dana-Farber's outstanding leadership in the EPA's WasteWise program, which helps organizations and businesses apply sustainable management practices to reduce industrial waste.

    Individuals

    William Hahn, MD, PhD, Dana-Farber's deputy chief scientific officer, was awarded the 39th annual AACR-Richard and Hinda Rosenthal Memorial Award, given by the American Association for Cancer Research. The award honors investigators age 50 or younger whose research "has made, or promises to soon make, a notable contribution to improved clinical care in the field of cancer."

    Dana-Farber genitourinary oncology researcher Eliezer Van Allen, MD, has received the Kure-It-AACR Research Grant for Immunotherapy in Kidney Cancer. The two-year grant, given by the American Association for Cancer Research, promotes and supports innovative research that advances the basic knowledge of tumor immunology and develops new treatment, control, or prevention tactics for kidney cancer.

    Dana-Farber's Ken Anderson, MD, has been selected as a fellow of the American Association for Cancer Research (AACR) Academy, which recognizes distinguished scientists who have driven progress in the fight against cancer.

    Three Dana-Farber faculty members were named to the 2014 class of "Giants of Cancer Care," a program sponsored by Intellisphere Oncology Specialty Group to honor researchers and educators whose discoveries have advanced the field of cancer treatment and care. The 16 awardees for 2014 include Ken Anderson, MD, George Demetri, MD, and Philip Kantoff, MD.

    Massachusetts Lawyers Weekly, Rhode Island Lawyers Weekly, and New England In-House have selected Richard S. Boskey as a 2015 "Leader in the Law." Boskey is Dana-Farber's senior vice president, general counsel, and chief governance officer.

    Dana-Farber and Boston Children's Hospital nurse Patti Branowicki, who passed away in August after a 13-year battle with ovarian cancer, has been named an honoree for "the one hundred" in 2015. The annual event, sponsored by Massachusetts General Hospital Cancer Center, honors individuals and groups from around the globe who have made significant contributions to fighting cancer.

    Angela Brooks, PhD, a Damon Runyon Fellow through 2015, is a recipient of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists.

    Dana-Farber's Assistant General Counsel, Ellen Farwell, has been elected president of the Women's Bar Foundation of Massachusetts (WBF).

    A recent study by Charles Fuchs, MD, MPH, director of the Gastrointestinal Cancer Center at Dana-Farber, is included in Clinical Cancer Advances 2015, a report by the American Society of Clinical Oncology (ASCO) that documents the year's major achievements and emerging trends in clinical cancer research and care.

    William Kaelin, MD, associate director for basic science at Dana-Farber, received the 2014 Steven C. Beering Award for outstanding contributions to biomedical or clinical science in a ceremony at Indiana University School of Medicine.

    Christopher Lathan, MD, MS, MPH, faculty director of the Cancer Care Equity Program at Dana-Farber and a medical oncologist in the Lowe Center for Thoracic Oncology, received the Harold Amos Faculty Diversity Award given by Harvard Medical School (HMS). The award, named after Harold Amos, the first African American department chair at Harvard Medical School, recognizes HMS and Harvard School of Dental Medicine (HSDM) faculty who are dedicated to making HMS and HSDM more diverse and inclusive communities.

    Leslie Lehmann, MD, of Dana-Farber/Boston Children's Pediatric Stem Cell Transplant Center, and pediatric oncology nurse Kathy Houlahan, MHA, MSN, RN, traveled to Washington, D.C., in December to request financial support for pediatric cancer care in Iraq. Lehmann and Houlahan, who spoke on behalf of Iraqi colleagues in Baghdad, testified at a hearing held by the Thomas Lantos Human Rights Commission (TLHRC).

    Franziska Michor, PhD, principal investigator at the Physical Science-Oncology Center at Dana-Farber, has been named a 2015 recipient of a Vilcek Foundation Creative Prize in Biomedical Science.

    Shuji Ogino, MD, PhD, MS, of Dana-Farber's Department of Medical Oncology, was promoted to full professor of pathology at Harvard Medical School (HMS), Dana-Farber, and http://www.brighamandwomens.org/" target="_blank">Brigham and Women's Hospital. He is also a faculty member in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health (HCSPH).

    Lawrence Shulman, MD, chief of staff and senior vice president of medical affairs at Dana-Farber and director of the Institute's Center for Global Cancer Medicine, was named to the board of directors of the LIVESTRONG Foundation, a role he will serve in for three years.

    Bruce Spiegelman, PhD, director of Dana-Farber's Center for Energy Metabolism and Chronic Disease and professor of cell biology and medicine at Harvard Medical School, has received Belgium's most important international scientific prize for his contributions to understanding the mechanisms of metabolic disorders. Queen Mathilde of Belgium presented Spiegelman with the 2015 Health Prize of the InBev-Baillet Latour Fund. The prize aims to "reward projects of high human value that hold hope and promise for the well-being of society."

    October 2014 – January 2015

    The Institute

    The Commission on Cancer (CoC) has recognized Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) for its dedication to providing quality care to its patients, and has accorded it a three-year accreditation. The accreditation includes access to the CoC's National Cancer Data Base and educational and training opportunities. The CoC is a consortium of professional organizations committed to improving survival rates and quality of life for cancer patients.

    Dana-Farber was one of a select group of 426 health care facilities nationwide to be named Leaders in LGBT Healthcare Equality by the Human Rights Campaign (HRC) Foundation, earning top marks again this year in meeting non-discrimination and training criteria that demonstrate its commitment to equitable, inclusive care for LGBT patients and their families, who can face significant challenges in securing the quality health care and respect they deserve.

    Dana-Farber's Program for Young Women with Breast Cancer, led by Ann Partridge, MD, MPH, was awarded a $1.75 million grant from the Division of Cancer Prevention and Control of the Centers for Disease Control and Prevention.

    Dana-Farber has been recognized for its delivery of high quality care and prevention of medical errors by The Leapfrog Group, which named the Institute to its list of Top Hospitals for 2014.

    Boston magazine has named 57 physicians and surgeons affiliated with Dana-Farber to its annual Top Doctors guide.

    The Breast Care Center and Multi-Specialty Clinics at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital received Beacon of Excellence and Guardian of Excellence awards from Press Ganey Associates Inc., a performance improvement firm.

    Individuals

    Franziska Michor, PhD, principal investigator at the Physical Science-Oncology Center at Dana-Farber, has been named a 2015 recipient of a Vilcek Foundation Creative Prize in Biomedical Science. The award, given to three individuals each year, recognizes young foreign-born biomedical scientists who have demonstrated outstanding achievement in basic, applied, and/or translational research.

    Mary-Ellen Taplin, MD, director of clinical research in Dana-Farber's Lank Center for Genitourinary Oncology, has won a Prostate Cancer Foundation (PCF) Challenge Award for the study, "Eliminating Lethal Micrometastatic Prostate Cancer through High Intensity Short Duration AR Suppression." Challenge Awards focus on improving the treatment of lethal prostate cancer by supporting multidisciplinary teams of researchers. Winners were selected based on the relevance of their clinical research and the potential of near-term impact on medical standard of care.

    George Demetri, MD, Philip Kantoff, MD, and Kenneth Anderson, MD, have been selected as "Giants of Cancer 2014" by the influential organization, OncLive. Giants are chosen by an exclusive advisory board made up of 29 oncology educators, clinicians, and researchers.

    Matthew Meyerson, MD, PhD, of Medical Oncology, has been awarded an American Cancer Society (ACS) Research Professorship, the most prestigious national research grant given by the ACS.

    Alexander Gimelbrant, PhD, of Cancer Biology, is one of eight recipients of a Transformative Research Award from the National Institutes of Health, which funds "inherently risky" research "that could potentially create or challenge existing paradigms."

    Cigall Kadoch, PhD, of Pediatric Oncology, was selected for the National Institutes of Health's New Innovator Award, supporting young investigators in pursuing "unusually innovative research."

    Dan Landau, MD, PhD, was selected to receive a training award from the National Institutes of Health's new Big Data to Knowledge (BD2K) initiative, which is supporting research in how best to use complex biomedical data sets produced by genomic technologies.

    The American Society of Hematology (ASH) recently awarded career development awards to three Dana-Farber staff members: Francesca Cottini, MD, a fellow with Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC); Alex F. Herrera, MD, also a DF/BWCC fellow; and Venée N. Tubman, MD, MMSc, a second-year instructor at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

    The Northeast Human Resources Association (NEHRA) recently awarded its 2014 John D. Erdlen Five Star Award to Deborah Hicks, senior vice president and chief human resources officer at Dana-Farber. The Five Star Award is presented each year to an individual who consistently demonstrates excellence in human resources through their leadership efforts, innovation, and professionalism.

    The Susan G. Komen® foundation in 2014 awarded grants to 10 Dana-Farber researchers: Rachel Freedman, MD, MPH; Judy Garber, MD, MPH; Ian Krop, MD, PhD; Ji Li, PhD; David Livingston, MD; Otto Metzger Filho, MD; Ann Partridge, MD, MPH; Shaokun Shu, PhD; Nadine Tung, MD; and Eric Winer, MD. The Dana-Farber researchers were among 50 Komen grant recipients nationwide. They will receive a total of nearly $2 million in funds intended to drive new treatments and discoveries.

    David G. Nathan, MD, president emeritus of Dana-Farber and physician-in-chief emeritus of Boston Children's Hospital, received the first Lifetime Impact Award established by Boston Children's Hospital.

    Todd Golub, MD; Margaret Shipp, MD; and Bruce Spiegelman, PhD, have been elected to the Institute of Medicine (IOM), a nongovernmental organization that advises the nation on issues related to biomedical science, medicine, and health.

    Kenneth C. Anderson, MD, director of Dana-Farber's Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, has been elected vice president of the American Society of Hematology (ASH) Executive Committee. Following his one-year term as vice president, Anderson will serve successive terms as president-elect and president of the committee.

    Curtis Chong, MD, PhD, a senior medical oncology fellow in the Lowe Center for Thoracic Oncology, was named a Fellow of the American College of Physicians (ACP), an honor that recognizes professionalism and scholarship in internal medicine.

    Deborah Hicks, senior vice president for Human Resources and chief human resources officer, was selected as a member of Gov.-elect Charlie Baker's transition team.

    David Williams, MD, a leader of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, was inducted as president of the American Society of Hematology (ASH), the world's largest professional society of hematologists.

    Myles Brown, MD; Alan Engelman, PhD; and Barrett Rollins, MD, PhD, have been named as fellows to the American Association for the Advancement of Science (AAAS), an honor that recognizes contributions to innovation, education, and scientific leadership.

    Lawrence Shulman, MD, chief of staff at Dana-Farber and director of the Institute's Center for Global Cancer Medicine, recently served as co-chair of the World Health Organization's (WHO) Working Group on Essential Medicines for Cancer in Geneva, Switzerland.

    Tom Kochanek, PhD, a member of the Adult Patient and Family Advisory Council; Sara Dickison Taylor, co-chair of its pediatric counterpart; and Pat Stahl, MEd, director of Volunteer Services and staff liaison to the councils, represented Dana-Farber at a recent seminar, "Moving Forward with Patient- and Family-Centered Care."

    James DeCaprio, MD, of Medical Oncology at Dana-Farber, has been promoted to full professor of medicine at Harvard Medical School.

    July – October 2014

    The Institute

    The Leapfrog Group has named Dana-Farber Cancer Institute to its annual list of Top Hospitals. An elite distinction awarded to hospitals nationwide for demonstrating excellence in hospital safety and quality, the Leapfrog Top Hospital Award is given to less than seven percent of all eligible hospitals.

    U.S. News and World Report's 2014-15 Best Hospitals Guide ranked Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) as the top cancer hospital in New England for the 14th year in a row, and the #4 cancer center overall in the country (up from #5 last year).

    Dana-Farber Cancer Institute earned Magnet® status from the American Nurses Credentialing Center (ANCC) for the third time. This prestigious designation recognizes excellence in nursing and health care delivery and has been given to only 7 percent of hospitals worldwide. In 2005, Dana-Farber became the first cancer center in New England to receive Magnet status.

    Dana-Farber's Longwood campus was awarded certification from The Quality Oncology Practice Initiative (QOPI®) — which is sponsored by The American Society of Clinical Oncology. Dana-Farber's main campus joins three satellite centers (Milford, South Shore, and Londonderry) that earned QOPI certification in 2013 for their medical oncology practices. Dana-Farber Community Cancer Care (DFCCC), a network of physician practices which Dana-Farber acquired July 1, 2014, is also certified by QOPI. The practice had already earned QOPI status under its former name, Commonwealth Hematology-Oncology.

    Dana-Farber/New Hampshire Oncology-Hematology (DF/NHOH) in Londonderry, N.H., earned a Readers' Choice Award from the New Hampshire Union Leader, New Hampshire's largest newspaper. The facility was named one of the best cancer centers in the state in a poll of more than 3,000 New Hampshire residents.

    Dana-Farber has been ranked #4 nationally in an analysis of the "Top 100 Most Social Media Friendly Hospitals for 2014," just behind Baylor Regional Medical Center and just above MD Anderson. Over 800 hospitals were evaluated according to Facebook and Twitter metrics to determine "which hospitals are doing the best job of connecting with patients through social media."

    Modern Healthcare awarded Dana-Farber/Brigham and Women's "You Have Us" advertising campaign a Silver Award for Integrated Marketing. Additionally, on the strength of that campaign, our advertising agency was named "Agency of the Year."

    A representative of the Joint Commission conducted an unannounced laboratory survey at Dana-Farber in July, noting a number of "best practices and outstanding services" during the two-day visit. The survey focused on services provided in the Core Laboratory, the Cell Manipulation Core Facility (CMCF), the Fanconi Anemia Clinical Laboratory, Yawkey 2 Lab Services and Yawkey 8 Infusion.

    The Cord Blood Donation Program at Dana-Farber Cancer Institute/Brigham and Women's Hospital was recently recognized by the Carolinas Cord Blood Bank (CCBB) at Duke University for its outstanding performance in umbilical cord blood banking.

    The Susan F. Smith Center for Women's Cancers at Dana-Farber received $342,143 from QVC Presents "FFANY (Fashion Footwear Association of New York) Shoes on Sale," an annual charitable shoe sale that raises funds and awareness for breast cancer organizations nationwide. Dana-Farber is one of nine beneficiaries of the 2013 event.

    Individuals

    Myles Brown, MD, Alan Engelman, PhD, and Barrett Rollins, MD, PhD, of Dana-Farber Cancer Institute have each been named a Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers.

    • Brown was elected for the discovery of key nuclear mechanisms that underlie the hormone dependence and the response to endocrine therapy of breast and prostate cancers.
    • Engelman was elected for significant contributions to the field of biological sciences, particularly in determining mechanisms of retroviral integration targeting and inhibition.
    • Rollins was elected for distinguished contributions to the field of leukocyte physiology, particularly for using genetics to define the role of chemoattractants and oncogenes in health and disease.

    Todd R. Golub, MD, Margaret A. Shipp, MD, and Bruce M. Spiegelman, PhD, of Dana Farber Cancer Institute, have been elected to the Institute of Medicine (IOM), a non-governmental organization that advises the nation on issues related to biomedical science, medicine, and health. Election to the IOM is considered one of the highest honors in the fields of health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service.

    Thomson Reuters ScienceWatch – a Web resource for science metrics and research performance analysis – recognized 19 basic scientists and clinical investigators at Dana-Farber for being among "the world's most influential scientific minds." The ranking was based on how frequently their research discoveries have been cited by peers in the past decade. The 19 Dana-Farber investigators were listed among 3,200 Highly Cited Researchers in 21 broad fields of science from 2002 to 2012:

    The Cancer Research Institute (CRI) honored Dana-Farber immunologist Gordon Freeman, PhD, and three other scientists, for a landmark discovery that opened a new avenue for fighting cancer with therapies that unleash the immune attack against tumors. The researchers received the William B. Coley Award for Distinguished Research in Tumor Immunology on Oct. 7 in New York City. The other award recipients are Tasuku Honjo, MD, PhD, of Kyoto University School of Medicine; Lieping Chen, MD, PhD, of Yale University School of Medicine; and Arlene Sharpe, MD, PhD, of Harvard Medical School and Dana-Farber/Harvard Cancer Center.

    Sapna Syngal, MD, MPH, director of the Gastrointestinal Cancer Genetics and Prevention Program at Dana-Farber and director of Gastroenterology at the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), was promoted to the rank of full professor of medicine at Harvard Medical School.

    Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology and scientific co-director of the Belfer Institute for Applied Cancer Science, was promoted to the rank of full professor of medicine at Harvard Medical School.

    Mary E. Cooley, PhD, APRN-BC, a nurse scientist in Dana-Farber's Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, was promoted to associate professor at the University of Massachusetts-Boston.

    Stuart Orkin, MD, chair of Pediatric Oncology at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, associate chief of the Division of Hematology/Oncology at Boston Children's Hospital, and David G. Nathan Professor of Pediatrics at Harvard Medical School, is the recipient of the William Allan Award from the American Society of Human Genetics (ASHG). Created in honor of William Allan, one of the first American physicians to conduct research in human genetics, the Allan Award is the ASHG's highest honor, and recognizes the recipient's significant contributions to the field of genetics. Orkin's laboratory researches the genetics of blood disorders, mainly how blood cells form and how they decide to develop into different blood types and disorders. This work applies to both inherited anemia and acquired disorders, such as leukemia, that affect children and adults. Orkin will receive the award and a $10,000 prize.

    Fourteen Dana-Farber clinical faculty members earned promotions in 2014 as part of a new Institute effort to recognize the accomplishments of faculty who devote significant time to their clinical practice. The Clinical Promotions Committee implemented Institute titles for clinical faculty in 2012 to create an advancement structure within the Institute and acknowledge clinicians whose work may not be fully recognized through the Harvard Medical School promotion system:

    Dana-Farber was awarded a three-year, $1.5 million grant from the Ben and Catherine Ivy Foundation, which will enable Dana-Farber researchers to prepare a multi-pronged attack on glioblastoma brain tumors with a combination of immunotherapy methods. This includes a small pilot clinical trial of a cutting-edge vaccine (NeoVax) being conducted by a team led by David Reardon, MD, clinical director of Dana-Farber's Center for Neuro-Oncology.

    The Liddy Shriver Sarcoma Initiative selected Andrew Wagner, MD, PhD, for an international team grant aimed at improving the understanding and treatment of liposarcoma, a rare form of sarcoma. The two-year, $250,000 International Collaborative Grant is funded in partnership with The Wendy Walk.

    Seven Dana-Farber doctors were awarded research grants by the Melanoma Research Alliance (MRA). MRA is the largest private funder of melanoma research and this year awarded a record-breaking $8 million in new research grants. Dana-Farber doctors were awarded three Team Science Awards and one Academic Industry Award:

    Judy Garber, MD, MPH, director of the Center for Cancer Genetics and Prevention and a leader of Dana-Farber's Susan F. Smith Center for Women's Cancers, has been appointed to the National Institutes of Health (NIH) Council of Councils, which makes recommendations to the NIH director on areas of research that represent emerging scientific opportunities. She will represent the National Cancer Institute (NCI). Garber is one of nine new appointees to the 27-member council. They will serve through October 2016.

    Mark Zimmerman, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, was awarded the Damon Runyon-Sohn Pediatric Research Fellowship Award from the Damon Runyon Cancer Research Foundation. Zimmerman will receive $208,000 over four years to continue his research on the CHD5 gene, an attractive target for precision cancer drugs in treating neuroblastoma tumors.

    Alan D'Andrea, MD, Alvan T. and Viola D. Fuller American Cancer Society Professor of Radiation Oncology at Dana-Farber and Harvard Medical School, has been appointed to the National Cancer Institute's (NCI) Board of Scientific Counselors for Basic Sciences. Along with other board members, D'Andrea will advise the NCI director on scientific program policy, progress, and the future of cancer research.

    The St. Baldrick's Foundation awarded three grants totaling more than $1.3 million to Dana-Farber investigators to support their research to find cures and better treatments for pediatric cancers:

    • Two grants totaling $427,500 were awarded to Pratiti Bandopadhayay, MBBS, PhD, and Birgit Knoechel, MD, PhD. Bandopadhayay and her team are looking to identify drug combinations that can improve treatment for children with medulloblastoma, an aggressive type of brain tumor. Knoechel is studying patients diagnosed with T-cell Acute Lymphoblastic Leukemia (ALL), specifically, how effective a certain regulator is in reducing drug resistance in patients with T-cell ALL, with the goal of finding new ways to treat the disease.
    • St. Baldrick's also awarded a $951,085 consortium grant to Dana-Farber's Carlos Rodriguez-Galindo, MD, whose research focuses on langerhans cell histiocytosis (LCH), a rare type of neoplasm of the blood.

    The Lymphoma Research Foundation (LRF) named Margaret Shipp, MD, chief of Dana-Farber's Division of Hematologic Neoplasia and leader of the Dana-Farber/Harvard Cancer Center Lymphoma and Myeloma Program, to its Scientific Advisory Board (SAB). Shipp is one of six new members named to the 45-member SAB. Her five-year term began July 1, 2014.

    William Shih, PhD, was named a finalist for the 2014 Blavatnik National Awards for Young Scientists, which honors the country's most innovative young investigators. He was one of 30 finalists in three categories: life sciences, physical sciences and engineering, and chemistry.

    Alec Kimmelman, MD, PhD, received the second annual Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research. Given by Columbia University in memory of Ruth Leff Siegel, the award recognizes an investigator who has made the most significant contribution to pancreatic cancer research in the past year.

    Three of Dana-Farber's Pediatric Oncology researchers have been chosen to receive 2014 Innovation Grants from Alex's Lemonade Stand Foundation. Each will receive $250,000 over two years to support research on novel approaches to childhood cancer – projects that have been deemed "highly important" but have not received funding from the National Institutes of Health. The Innovation Grants are part of the foundation's Accelerator Programs, which work to advance the pace of innovative research:

    • Rani George, MD, PhD, of Pediatric Oncology, will use the support for a project, "Targeting MYC/MYCNdriven Transcriptional Amplification in Pediatric Cancer."
    • Thomas Look, MD, also of Pediatric Oncology, will use the funding for his studies on "The Role of LMO1 in Neuroblastoma Initiation and Maintenance: Analysis in the Zebrafish Model of Childhood Neuroblastoma."
    • Rosalind Segal, MD, PhD, of Cancer Biology, was chosen for her research project, "Therapies for SHH-subtype Medulloblastoma."

    Esther Obeng, MD, PhD, of Dana-Farber /Boston Children's Cancer and Blood Disorders Center, received four years of research support through an American Society of Hematology (ASH) fellowship. The award, which totals $420,000 in research funding, is the 2014 American Society of Hematology-Harold Amos Medical Faculty Development Program Fellowship. Obeng's research focuses on the role of certain mutations in causing blood cancers known as myelodysplastic syndromes (MDS).

    Dennis Buckley, PhD, and Mark Zimmerman, PhD, recently earned fellowships supporting their work from the Damon Runyon Cancer Research Foundation. Buckley, a postdoctoral fellow in the Dana-Farber lab of James Bradner, MD, received a four-year, $200,000 award to support his research into improved inhibitors of BET-bromodomain proteins for the treatment of cancers such as acute leukemia, hematological malignancies, NUT-midline carcinoma, and solid tumors. Zimmerman, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, received the Damon Runyon-Sohn Pediatric Research Fellowship Award, which will provide $208,000 over four years to continue his research on the CHD5 gene, an attractive target for precision cancer drugs in treating neuroblastoma tumors.

    Ken Anderson, MD, director of the Dana-Farber/Brigham and Women's Cancer Center Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics, was appointed to the Board of Scientific Advisors of the National Cancer Institute (NCI). Anderson was also appointed to the Institute of Medicine's National Cancer Policy Forum, where he will help ensure scientific and clinical advances quickly make their way to cancer patients.

    Mark Kieran, MD, PhD, clinical director of the Pediatric Brain Tumor Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and associate professor of pediatrics at Harvard Medical School, was named to the new Research Advisory Network of the Pediatric Brain Tumor Foundation. He joins 16 other medical, research, and pharmaceutical leaders on this volunteer network.

    Carl Novina, MD, PhD, a researcher in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute, is one of 10 scientists chosen to receive a 2014 National Institutes of Health Pioneer Award, which funds bold and innovative research proposals to attack challenging biomedical problems.

    Deborah Hicks, Senior Vice President of Human Resources and Chief Human Resource Officer, was awarded the John D. Erdlen Five Star Award by the Northeast HR Association (NEHRA). The award recognizes an individual who has consistently demonstrated excellence in Human Resources through their leadership efforts. Nominees must have a minimum of 10 years of HR experience and made significant contributions to the profession through their leadership.

    Donna Berry, PhD, RN, NEA-BC, FAAN, director of the Phyllis F. Cantor Center for Nursing and Patient Care Services, was awarded the 2014 Friends of the National Institute of Nursing Research (FNINR) President's Award. Only four distinguished nurse research awards are granted each year.

    April – July 2014

    The Institute

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center is the nation's #1-ranked pediatric cancer program, according to U.S.News & World Report's 2014-15 Best Children's Hospitals report. Boston Children's Hospital ranked first in eight of the 10 categories — including cancer — that U.S. News evaluates, more than any other children's hospital in the United States.

    The Quality Oncology Practice Initiative (QOPI®) Certification Program has awarded Dana-Farber Cancer Institute a three-year certification for meeting the highest standards for quality cancer care at our main campus in the Longwood Medical Area. Our satellite centers in Milford, Londonderry, and South Weymouth were certified in 2013, and our recently acquired physician practice – Dana-Farber Community Cancer Care – also holds QOPI certification. The QOPI Certification Program is the first certification for outpatient oncology practices in the United States. The program was developed by the American Society of Clinical Oncology (ASCO), the world’s leading professional oncology organization. To earn certification, a cancer care facility must undergo an evaluation of its entire practice and documentation standards to ensure that it is providing the best possible patient care, and that it demonstrates a commitment to excellence and ongoing quality improvement.

    Dana-Farber has earned Magnet® status from the American Nurses Credentialing Center (ANCC) for the third time. This prestigious designation recognizes excellence in nursing and health care delivery.

    Joining a series of leaders from politics, education, music, and sports, Dana-Farber President Edward J. Benz Jr., MD, shared the breakthroughs and challenges of personalized cancer treatment as part of a TEDx event at the University of Massachusetts Boston. In keeping with the theme of the April 30 symposium, "Lighting the Way for the Future," Benz discussed the next steps in cancer research and care.

    Individuals

    Alex's Lemonade Stand Foundation (ALSF), a nonprofit dedicated to finding cures for children with cancer, has awarded 2014 Innovation Grants of $250,000 each over two years to Rani George, MD, PhD, for "Targeting MYC/MYCN-driven Transcriptional Amplification in Pediatric Cancer"; to Thomas Look, MD, for "Role of LMO1 in Neuroblastoma Initiation and Maintenance: Analysis in the Zebrafish Model of Childhood Neuroblastoma"; and to Rosalind Segal, MD, PhD, for "Therapies for SHH-subtype Medulloblastoma".

    The Cancer Research Institute will bestow its top scientific prize for breakthrough discoveries in cancer immunotherapy to Gordon Freeman, PhD, at its annual awards dinner. Dr. Freeman and three other researchers will receive the prize for their collective contributions to the discovery of the programmed cell death-1 (PD-1) receptor pathway, a new immune system checkpoint that has been shown in clinical studies to be a highly promising target in cancer immunotherapy.

    The annual meeting of the American Association for Cancer Research (AACR), held in San Diego, cast a spotlight on the work of Dana-Farber scientists. Some highlights:

    • Stand Up To Cancer and the Farrah Fawcett Foundation announced a research grant to a team led by Dana-Farber's Ellis L. Reinherz, MD, and Robert I. Haddad, MD.
    • Leena Gandhi, MD, PhD, of Medical Oncology, presented research on a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that unleashes an immune system attack on tumor cells.
    • William Kaelin, Jr., MD, chair of the Executive Committee for Research at Dana-Farber; Frederick Li, MD, an emeritus member of the Dana-Farber faculty; and David Livingston, MD, deputy director of Dana-Farber/Harvard Cancer Center, were formally inducted as elected fellows of the AACR Academy.
    • The AACR and its Minorities in Cancer Research membership group awarded Levi Garraway, MD, PhD, of Medical Oncology, with the Jane Cooke Wright Lectureship. The lectureship recognizes outstanding scientists who have made meritorious contributions to the field of cancer research and who have, through leadership or by example, furthered the advancement of minority investigators in cancer research.

    The 50th annual meeting of the American Society of Clinical Oncology (ASCO) was attended by 33,000 physicians and scientists from the U.S. and abroad, as well as a cohort of journalists, patient advocates, and biotech and pharmaceutical company representatives. Dana-Farber researchers presented results from dozens of ongoing and completed studies. Here is some of the research they presented:

    • Joyce Liu, MD, MPH, of the Susan F. Smith Center for Women's Cancers reported that, in a phase 2 clinical trial, a combination of olaparib (a drug that blocks DNA repair in cancer cells) and cediranib (which blocks blood vessel growth in tumors) was considerably more effective in women with recurrent ovarian cancer than olaparib alone.
    • Christopher Sweeney, MBBS, of the Lank Center for Genitourinary Oncology, reported that, in a phase 3 trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment rather than waiting for the disease to become resistant to hormone-blocking agents.
    • Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology, presented data from a phase 1 trial showing that a new, more precisely targeted drug shrank tumors in about half of non-small cell lung cancer patients whose tumors no longer responded to conventional targeted drugs.
    • F. Stephen Hodi, MD, director of the Melanoma Treatment Center, reported that the immunotherapy drug nivolumab continues to have long-term effectiveness against metastatic melanoma, achieving a three-year survival rate of 41 percent in patients participating in a phase 1 trial of the drug.

    Several Dana-Farber faculty members also received awards at the meeting. They include: Ann Partridge, MD, MPH, director of the Institute's Adult Survivorship Program, who was named an ASCO Fellow; Andrew Place, MD, PhD, who received the James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology, given to the junior faculty member who submitted the highest-ranking research abstract in pediatric oncology as determined by the ASCO Scientific Program Committee; and Matthew Davids, MD, who received a Career Development Award. Young Investigator Awards were bestowed on Franklin Huang, MD, Junne Kamihara, MD, PhD, and Kent Mouw, MD, PhD.

    Ken Anderson, MD, was honored by the Samuel Waxman Cancer Research Foundation for his research in developing novel therapies for forms of cancer that are notoriously difficult to treat. He received the David T. Workman Memorial Award on May 12 at Mount Sinai Hospital in New York City. Anderson was also named the 2014 Zubrod Distinguished Guest Lecturer by the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

    George Canellos, MD, William Rosenberg Professor of Medicine at Harvard Medical School and senior physician in the Adult Lymphoma Program at Dana-Farber/Brigham and Women's Cancer Center, was recognized with an honorary doctorate in humanities from the Hellenic College Holy Cross Greek Orthodox School of Theology in Brookline, Massachusetts, where he also delivered the commencement address May 17.

    A new book co-edited by clinical fellow Curtis Chong, MD, PhD, is becoming standard equipment for many primary care providers in the United States and abroad. Pocket Primary Care, published in March, is a concise point of reference for physicians, nurse practitioners, physician assistants, and other professionals working in outpatient settings.

    George Demetri, MD, senior vice president for Experimental Therapeutics and director of the Center for Sarcoma and Bone Oncology, received the Sarcoma Foundation of America's 2014 Vision of Hope Award at the foundation's 12th Annual Gala on May 5 in New York City.

    Three Dana-Farber researchers were among 32 grant recipients at the annual American Association for Cancer Research (AACR) meeting, held in April in San Diego, California. Hugh S. Gannon, PhD, in the laboratory of Matthew Meyerson, MD, PhD, received the AACR Anna D. Barker Fellowship in Basic Cancer Research grant. Marios Giannakis, MD, PhD, in the laboratory of Levi Garraway, MD, PhD, was awarded the Colon Cancer Alliance-AACR Fellowship for Biomarker Research. Andrew Lee Hong, MD, in the lab of William C. Hahn, MD, PhD, received the AACR-Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award.

    Wolfram Goessling, MD, PhD, David Rosenthal, MD, and the Dana-Farber/Harvard Cancer Center Faith-Based Cancer Disparities Network were recently named honorees at "the one hundred" gala, an annual event sponsored by Massachusetts General Hospital Cancer Center. The program celebrates individuals and organizations leading the fight against cancer.

    Eva Guinan, MD, director of translational research in Radiation Oncology at Dana-Farber and former director of the Stem Cell Transplant Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, was promoted to full professor of radiation oncology at Harvard Medical School.

    Nancy Hilton, RN, MS, director of nursing and clinical services for Yawkey 10, Yawkey 6, and Imaging, is one of two nurses selected to represent the Oncology Nursing Society on the Ambulatory Care Professional and Technical Advisory Committee of the Joint Commission.

    Four Dana-Farber researchers recently received Young Investigator Grants from Alex's Lemonade Stand Foundation. The two-year grants of $100,000 help investigators pursue promising research in treatments for childhood cancer. The Dana-Farber grant recipients include:

    • Zhaodong Li, PhD, who is studying the biology of T-cell acute lymphoblastic leukemia to identify new, targeted therapies to treat the disease
    • Brenton Mar, MD, PhD, who is studying chemotherapy resistance in relapsed acute lymphoblastic leukemia
    • Yana Pikman, MD, who is studying new therapies for acute myeloid leukemia
    • Kristopher Sarosiek, PhD, who is working to prevent brain and heart damage induced by radiation or chemotherapy treatments in pediatric cancer patients

    Nikhil C. Munshi, MD, director for basic and correlative sciences and associate director of Dana-Farber/Brigham and Women's Cancer Center's Jerome Lipper Myeloma Center, has been promoted to full professor in medical oncology at Harvard Medical School.

    May 6 kicked off National Nurses Week. Each year, the Boston Globe compiles a "Salute to Nurses" that highlights some of the front-line clinicians, nominated by patients and colleagues, who work in area hospitals. The following Dana-Farber nurses were honored this year:

    • Infusion 10th floor
    • Shahrzad Bahrehmand, RN, BSN
    • Annie Beauchemin, RN
    • Kerry Beliveau, RN, BSN
    • Brenda Biggins, BSN
    • Marianne Castano, RN, BSN
    • Michael Comeau, MSN, CPON 
    • Heather Cushing, RN, BSN, OCN
    • Rachel Enos, RN
    • Kristen Graham, BSN, RN, CPON
    • Allison Hester, RN, BSN, OCN
    • Catherine Hulme-Freudenberger, RN, BSN, MS
    • Robin MacNeil, RN, BSN
    • Cullene Murphy, RN, BSN, OCN
    • Diane Ransom, RN, BSN, OCN
    • Caroline Sheehan, RN, BSN
    • Larry Traiman, RN
    • Christin Whalenn, RN, BSN, OCN
    • Marie Zano, RN, BSN, OCN

    Amanda Randles, PhD, visiting scientist in Biostatistics and Computational Biology at Dana-Farber and a Lawrence Fellow at Lawrence Livermore National Laboratory, addressed the role of supercomputers in diagnosing heart disease at the Cambridge Science Festival's annual Big Ideas for Busy People event.

    Ramesh Shivdasani, MD, PhD, physician-scientist in the Center for Gastrointestinal Oncology, was promoted to the rank of full professor of medicine at Harvard Medical School.

    Glorian Sorensen, MD, MPH, has received federal funding for research on smoking cessation measures in India. This pilot study builds on a previous study funded by the National Cancer Institute (NCI) that showed the efficacy of a tobacco use cessation intervention with schoolteachers, who are key opinion leaders in their communities.

    Kimberly Stegmaier, MD, associate professor of pediatrics at Harvard Medical School and pediatric oncologist at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, received a Clifford Barger Excellence in Mentoring Award from Harvard Medical School (HMS). Fifteen other Dana-Farber faculty members were nominated for HMS mentoring awards, including Brian Alexander, MD, MPH; Tracy Balboni, MD, MPH; Dipanjan Chowdhury, PhD; Irene Ghobrial, MD; Harley Haynes, MD; Philip Kantoff, MD; A. Thomas Look, MD; Paul Nguyen, MD; Nikhil Ramaiya, MD; Jerome Ritz, MD; Carlos Rodriguez-Galindo, MD; Barrett Rollins, MD, PhD; Stephen E. Sallan, MD; Rosalind Segal, MD, PhD; and Catherine Wu, MD.

    Kasisomayajula "Vish" Viswanath, PhD, associate professor in the Division of Population Sciences at Dana-Farber and in social and behavioral sciences at the Harvard School of Public Health (HSPH), was promoted to the rank of full professor of health communications at HSPH.

    Xiaofeng Wang, PhD, a pediatric research fellow at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, has been awarded a $50,000 grant from the Rally Foundation for Childhood Cancer Research for research on a lethal cancer of early childhood.

    The U.S. Department of Health and Human Services has appointed David Weinstock, MD, to serve on the National Biodefense Science Board, an advisory group that provides recommendations on federal disaster preparedness.

    Susan Wills, clinical strategic sourcing lead in Materials Management, and her Product Standards team received an Amerinet Healthcare Achievement Award. Wills and her team implemented a product conversion process and accompanying checklist, as a way to convert to new clinical products more efficiently.

    Kwok-Kin Wong, MD, PhD, of the Lowe Center for Thoracic Oncology and scientific director of the Belfer Institute for Applied Cancer Science at Dana-Farber, was promoted to the rank of full professor of medicine at Harvard Medical School.

    Two researchers have received a $100,000 grant to test a novel combination of therapies in Dana Farber/Brigham and Women's Cancer Center (DF/BWCC) patients with chronic graft-versus-host disease resulting from stem cell transplant. John Koreth, MBBS, DPhil, a medical oncologist in the Dana-Farber/Brigham and Women's Adult Stem Cell Transplantation Program, and William Savage, MD, PhD, medical director of therapeutic apheresis at Brigham and Women's Hospital, received the grant from Fresenius-Kabi, a global health care company.

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms